Relationship between Serum Glial Fibrillary Acidic Protein and Neurogranin Levels and Cognition in Multiple Sclerosis

Abstract

Multiple sclerosis is an inflammatory neurodegenerative disorder, and cognitive problems occur in the early and late phases of the disease. The purpose of this study was to investigate the relationship between serum glial fibrillary acidic protein and neurogranin levels and cognition in patients with multiple sclerosis (MS). Twenty-three patients and 25 healthy controls were included in the study. Serum glial fibrillary acidic protein (GFAP) and neurogranin (NRGN) levels were determined on blood samples from patients and controls. Disease duration and EDSS scores of patients were recorded, and the Montreal Cognitive Assessment (MOCA) scale was used for cognitive assessment. There was no statistically significant difference between the two groups in terms of serum NRGN and GFAP levels. MOCA scores were lower in the patient group than in the healthy control group. No statistically significant correlation was found between NRGN and GFAP serum levels and MOCA scores. Our study showed that there was no statistically significant association between serum NRGN and GFAP levels and cognition in MS patients. This study is the first to examine serum GFAP and NRGN levels in the context of cognition in MS.